Skip to main content
SpringerLink
Log in

Therapy of Multiple Sclerosis

  • Chapter
  • First Online:
Neuropsychiatric Dysfunction in Multiple Sclerosis

  • 1054 Accesses

Abstract

Currently there are no therapies able to heal Multiple Sclerosis (MS). However, depending on the stage and course of the disease, there are treatments available that can efficiently treat relapses, reduce relapse rate and, partially, disability progression, and improve some symptoms. This means that we are able to change the overall course of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sellebjerg F, Barnes D, Filippini G et al (2005) EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 12(12):939–946

    Article  PubMed  CAS  Google Scholar 

  2. Weinshenker BG, O’Brien PC, Petterson TM et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886

    Article  PubMed  CAS  Google Scholar 

  3. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7):1277–1285

    Article  Google Scholar 

  4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498–1504

    Article  Google Scholar 

  5. Schwid SR, Goodman AD, Mattson DH (1997) Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 54(9):1169–1190

    Article  PubMed  CAS  Google Scholar 

  6. Rotondi M, Oliviero A, Profice P et al (1998) Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 21(11):748–752

    PubMed  CAS  Google Scholar 

  7. Durelli L, Ferrero B, Oggero A et al (1999) Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 162(1):74–83

    Article  PubMed  CAS  Google Scholar 

  8. Yoshida EM, Rasmussen SL, Steinbrecher UP et al (2001) Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 56(10):1416

    Article  PubMed  CAS  Google Scholar 

  9. Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 46(2):197–206

    Article  PubMed  CAS  Google Scholar 

  10. Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 343(13):898–904

    Article  PubMed  CAS  Google Scholar 

  11. Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582

    Article  PubMed  CAS  Google Scholar 

  12. Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249

    Article  PubMed  CAS  Google Scholar 

  13. Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397

    Article  PubMed  CAS  Google Scholar 

  14. Panitch H, Miller A, Paty D et al (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63(10):1788–1795

    Article  PubMed  Google Scholar 

  15. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 56(11):1496–1504

    Article  Google Scholar 

  16. Sørensen PS, Deisenhammer F, Duda P et al (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12(11):817–827

    Article  PubMed  Google Scholar 

  17. Johnson KP, Brooks BR, Cohen JA et al (2001) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 57(12 Suppl 5):S16–S24

    PubMed  CAS  Google Scholar 

  18. Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511

    Article  PubMed  CAS  Google Scholar 

  19. O’Connor P, Filippi M, Arnason B et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8(10):889–897

    Article  PubMed  Google Scholar 

  20. Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903–914

    Article  PubMed  CAS  Google Scholar 

  21. Johnson KP, Brooks BR, Cohen JA et al (2001) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 57((12 Suppl 5)):S46–S53

    PubMed  CAS  Google Scholar 

  22. Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910

    Article  PubMed  CAS  Google Scholar 

  23. Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354(9):924–933

    Article  PubMed  CAS  Google Scholar 

  24. Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6(5):431–441

    Article  PubMed  Google Scholar 

  25. Neuhaus O, Kieseier BC, Hartung HP (2006) Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 109(1–2):198–209

    Article  PubMed  CAS  Google Scholar 

  26. Millefiorini E, Gasperini C, Pozzilli C et al (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244(3):153–159

    Article  PubMed  CAS  Google Scholar 

  27. Casetta I, Iuliano G, Filippini G (2009) Azathioprine for multiple sclerosis. J Neurol Neurosurg Psychiatry 80(2):131–132

    Article  PubMed  CAS  Google Scholar 

  28. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402–415

    Article  PubMed  CAS  Google Scholar 

  29. Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401

    Article  PubMed  CAS  Google Scholar 

  30. Zivadinov R, Ramanathan M, Dolic K et al (2011) Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother 11(9):1277–1294

    Article  PubMed  Google Scholar 

  31. Peuckmann V, Elsner F, Krumm N et al (2010) Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 11:CD006788

    PubMed  Google Scholar 

  32. Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68(4):494–502

    Article  PubMed  CAS  Google Scholar 

  33. Goodman AD, Brown TR et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373(9665):732–738

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second University of Naples, Naples, Italy

    Prof. Alessandro d’Ambrosio & Prof. Simona Bonavita

Authors
  1. Prof. Alessandro d’Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Simona Bonavita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simona Bonavita .

Editor information

Editors and Affiliations

  1. IRCCS, Fondazione Santa Lucia, Via Ardeatina 306, Roma, 00179, Italy

    Ugo Nocentini

  2. IRCCS, Fondazione Santa Lucia, Via Ardeatina 306, Roma, 00179, Italy

    Carlo Caltagirone

  3. Istituto di Scienze, Neurologiche, Seconda Univ. di Napoli, Via Pansini 5, Napoli, 80131, Italy

    Gioacchino Tedeschi

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Italia

About this chapter

Cite this chapter

d’Ambrosio, A., Bonavita, S. (2013). Therapy of Multiple Sclerosis. In: Nocentini, U., Caltagirone, C., Tedeschi, G. (eds) Neuropsychiatric Dysfunction in Multiple Sclerosis. Springer, Milano. https://doi.org/10.1007/978-88-470-2676-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2676-6_9

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2675-9

  • Online ISBN: 978-88-470-2676-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation